CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/first-line-chemotherapy-options-in-metastatic-pdac/33135/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens ha…

CME credits: 0.25 Valid until: 16-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/second-line-chemotherapy-options-in-metastatic-pdac/33136/ Pancreatic ductal adenocarcinoma, also known as PDAC, is a lethal disease that is usually diagnosed at an advanced stage with an extremely poor prognosis. Advancements in treatment regimens h…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longe…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and l…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-te…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term …

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects …

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and lo…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term b…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effe…

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effe…

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodol…

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timi…

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/distinguishing-between-anti-pd-1-agents-in-escc-combination-therapies/29790/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint in…

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/effective-monitoring-and-management-of-adverse-effects-in-metastatic-escc/29792/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoin…

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-importance-of-pd-l1-testing-shaping-the-future-of-treatment-in-escc/29791/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint …

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/the-impact-of-first-line-treatment-on-subsequent-treatment-options-for-metastatic-escc/33031/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an imm…

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and meth…

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-first-line-regimens-patient-centric-selection-in-metastatic-escc/33030/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoi…

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MutationalTestinginmCRcMethodsandDataDrivingTreatmentSelection/32942/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular t…

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/strategies-for-navigating-first-line-treatment-selection-in-metastatic-escc/33029/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpo…

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-guidelines-to-practice-first-line-treatment-choices-in-mcrc/32943/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular…

CME credits: 0.75 Valid until: 31-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/ici-combination-regimens-for-first-line-treatment-of-metastatic-escc/33028/ This online CME activity focuses on the first-line treatment of advanced or metastatic esophageal squamous cell carcinoma (ESCC) with the addition of an immune checkpoint inh…

CME credits: 0.50 Valid until: 26-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/antibody-drug-conjugates-in-bladder-cancer-guideline-updates-and-adverse-event-management/29174/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunothera…

CME credits: 1.00 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-insights-to-solve-the-puzzle-of-bladder-cancer/30062/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will g…

CME credits: 1.50 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/factoring-solutions-to-the-management-of-stroke-care-in-the-settings-of-secondary-prevention-and-af/29099/ Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-r…

CME credits: 1.00 Valid until: 13-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-care-within-the-rcc-treatment-paradigm/29528/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores the latest advances in risk stratification and evidence-based approaches for managing adva…

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/is-it-nonresponsiveprogressive-ism/32714/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosis, subclassification, …

CME credits: 0.25 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/advancing-multidisciplinary-care-in-tgct-integrating-systemic-therapies-and-surgical-approaches/29871/ In this activity, a medical oncologist and orthopedic surgeon discuss evidence-based surgical and systemic therapy approaches for the treatment of …

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-treatment-of-systemic-mastocytosis-with-an-associated-hematologic-neoplasm/32715/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has sig…

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/accurate-diagnosis-and-management-of-hereditary-alpha-tryptasemia/32716/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the…

CME credits: 0.50 Valid until: 28-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/differential-diagnosis-of-indolent-systemic-mastocytosis/32713/ The identification of KIT D816V mutation as a key driver for the expansion and accumulation of neoplastic mast cells in systemic mastocytosis (SM) has significantly improved the diagnosi…

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/exploring-new-and-emerging-treatments-in-muscle-invasive-bladder-cancer/32676/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line t…

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/reviewing-the-latest-bladder-cancer-practice-guidelines/32675/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for met…

CME credits: 0.50 Valid until: 21-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-perspectives-on-bladder-cancer/32677/ New understanding of molecular targets has helped transform invasive bladder cancer treatment, and guidelines now recommend chemotherapy-free immunotherapy as first-line treatment for metastatic bladder c…

CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/dont-miss-it-rapid-accurate-aav-diagnosis/32348/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This makes …

CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-patients-with-aav-in-the-rheumatology-clinic/32353/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement.…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-af-data-into-everyday-clinical-practice/32299/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living wi…

CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/tailoring-treatment-for-optimal-outcomes-in-patients-with-aav/32351/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ invo…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/how-do-we-translate-real-world-vte-data-into-everyday-clinical-practice-for-ongoing-anticoagulation/32303/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of peop…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-obesity-and-vte/32305/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing veno…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-obesity/32301/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous throm…

CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implementing-the-soc-induction-therapies-in-aav/32349/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This …

CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/elevating-care-for-patients-with-severe-renal-disease-in-aav/32352/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ invol…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-study-elderly/32300/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developing venous throm…

CME credits: 0.75 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-aav-outcomes-maintenance-therapies/32350/ Blood vessel inflammation that occurs with anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis – or AAV – often results in damage that can lead to multi-organ involvement. This ma…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/trade-off-ischemicthrombotic-vs-bleeding/32297/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of developin…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/setting-the-stage-of-real-world-data-vs-rct/32296/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because a significant number of people globally who are living with AF are at risk of develo…

CME credits: 1.00 Valid until: 14-02-2026 Claim your CME credit at https://reachmd.com/programs/cme/implications-associated-with-integrating-both-real-world-data-and-clinical-trial-data-into-clinical-practice-vte-considerations/32302/ The effective management of atrial fibrillation (AF) remains a high priority for many clinicians worldwide because …